gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NYSE · PBHHealthcarePharmaceuticals

Prestige Consumer Healthcare Inc. (PBH)

$49.54−0.38%
Close Nov 3, 2026 · split-adjusted
Oct 30, 2026$49.06▼ 19.02% in range
Nov 3, 2025Low $44.77 · High $70.21Oct 30, 2026
What changed · written from our data
As of Nov 3, 2026

Prestige Consumer Healthcare closed at $49.54 on Nov 3, down 0.38%, 29.4% below its 52-week closing high. Volume of 610.5K shares was 1.16× its 20-day average (close to normal).

Split-adjusted performance: +8.6% over one month, -11.1% over six months, -18.3% over one year.

In the quarter ended Jun 30, 2026, revenue was $265.71M, up 6.5% from a year earlier, with a net margin of 11.0%.

Short interest was 4.0M shares at the Oct 15 settlement, down 14.7% from the prior report (8.5% of float, 7.2 days to cover).

Market cap$2.35B47.4M shares
Revenue · quarter$265.7M+6.5% YoY
Diluted EPS$0.61−35.8% YoY
P/E · TTM13.6×P/S 2.1×
Net margin11.0%Gross 51.3%
Dividend yieldNone$0.3125 last paid
52-week range44.77 – 70.21−29.4% from high
Volume610.5K1.16× 20-day avg
Volatility · 60d30.1%Annualised
Short % of float8.5%7.3 days to cover
Net cash-$1.95BCash $89.1M
Next earnings—Not scheduled
Split-adjusted performance
1W +4.5%1M +8.6%3M −6.5%6M −11.1%YTD −19.7%1Y −18.3%3Y −15.8%5Y −17.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum63
Revenue growth51
Net margin82
Value (low P/E)58
Size84

Industry medians: 6-month return −26.5%, revenue growth +6.4%, net margin −38.1%, P/E 16.4×.

Short interest

Details →
Shares short4.0M−14.7% vs prior
Days to cover7.3Settled Oct 15
% of float8.5%
Short vol. 10d63.7%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
PBHPrestige Consumer Healthcare$49.54−0.38%−11.1%+6.5%11.0%13.6$2.35B
BHVNBiohaven$15.61+2.97%+60.8%———$2.36BCompare
NAMSNewAmsterdam Pharma Company N.V$19.90+1.74%−33.3%−80.7%−1732.9%—$2.38BCompare
IMNMImmunome$20.31+3.68%−12.1%−100.0%——$2.40BCompare
RCUSArcus Biosciences$18.91+5.94%−27.4%−74.4%−222.0%—$2.41BCompare
XNCRXencor$30.64+3.30%+138.4%+17.5%−42.4%—$2.28BCompare
TRLVTrulieve Cannabis$11.54+3.96%——−149.8%—$2.22BCompare
AUPHAurinia Pharmaceuticals$16.56+2.60%+3.2%+13.9%37.9%7.1$2.22BCompare
VERAVera Therapeutics$30.71+1.52%−11.0%———$2.21BCompare

News about Prestige Consumer Healthcare

All news →
Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now?Zacks Investment Research · Oct 15, 2026NeutralPBH vs. NEOG: Which Stock Is the Better Value Option?Zacks Investment Research · Sep 30, 2026▲ PositiveIs This the Right Time to Add PBH Stock to Your Portfolio?Zacks Investment Research · Sep 2, 2026▲ PositivePrestige Consumer Healthcare Inc. Completes Acquisition of LaCorium Health, Prices $400 Million Senior Notes Offering, and Announces First Quarter Fiscal 2027 Earnings Results DateGlobeNewswire Inc. · Jul 6, 2026▲ PositivePrestige Consumer Healthcare Inc. (PBH) Clear Eyes® and Pillar5 Problems Drive Stock Lower, Hagens Berman InvestigatingGlobeNewswire Inc. · Jun 23, 2026▼ Negative

Quick answers

What does Prestige Consumer Healthcare do?
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories.
What is PBH's market cap?
$2.35B, based on the Nov 3 close of $49.54.
What is PBH's P/E ratio?
13.6× trailing-twelve-month earnings of $172.01M.
Does Prestige Consumer Healthcare pay a dividend?
No regular cash dividend has been paid in the last year.
How much of PBH is sold short?
4.0M shares, 8.5% of float, as of Oct 15, 2026.
What sector is PBH in?
Healthcare, in the Pharmaceuticals industry.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.

HQ: Tarrytown, NY890 employeesListed Feb 10, 2005prestigebrands.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology